2 June 2022 in Journal of Experimental Medicine
Pancreatic β cell plasticity is the primary determinant of disease progression and remission of type 2 diabetes (T2D). However, the dynamic nature of β cell adaptation remains elusive. Here, we establish a mouse model exhibiting the compensation-to-decompensation adaptation of β cell function in response to increasing duration of high-fat diet (HFD) feeding. Comprehensive islet functional and transcriptome analyses reveal a dynamic orchestration of transcriptional networks featuring temporal alteration of chromatin remodeling. Interestingly, prediabetic dietary intervention completely rescues β cell dysfunction, accompanied by a remarkable reversal of HFD-induced reprogramming of islet chromatin accessibility and transcriptome. Mechanistically, ATAC-based motif analysis identifies CTCF as the top candidate driving dietary intervention–induced preservation of β cell function. CTCF expression is markedly decreased in β cells from obese and diabetic mice and humans. Both dietary intervention and AAV-mediated restoration of CTCF expression ameliorate β cell dysfunction ex vivo and in vivo, through transducing the lipid toxicity and inflammatory signals to transcriptional reprogramming of genes critical for β cell glucose metabolism and stress response.
1 July 2025 in International Journal of Nanomedicine
Lipopolysaccharide (LPS) is a unique component of the outer wall of gram-negative bacteria and is a complex composed of lipids and polysaccharides. Normally, liver sinusoidal endothelial cells (LSECs) systemically clear LPS via unknown mechanisms. However, under pathological conditions, LPS causes lethal endotoxemia if it cannot be rapidly cleared from the blood circulation. Currently, an increasing number of drugs have demonstrated the ability to clear or neutralize LPS. However, due to their inherent characteristics, such as low biocompatibility and short half-life, their clinical applications are limited. Nanodrug delivery systems have the advantages of improving pharmacokinetics, increasing bioavailability, reducing the occurrence of side effects, and prolonging drug circulation time, which can compensate for the shortcomings of traditional drugs. This review summarizes nanodrug delivery systems that can clear or neutralize LPS, such as polymer nanodrug delivery systems, lipid-based nanodrug delivery systems, peptide-based nanodrug delivery systems, inorganic nanodrug delivery systems, nanosponges, and extracellular vesicles, which provides an outlook on the application and future prospects of nanodrug delivery systems for clearing and neutralizing LPS.
2 November 2020 in BMC Medical Genomics
Background: The goal of our study is to investigate whether the methylation levels of AHCY and CBS promoters are related to the risk of cerebral infarction by detecting the methylation level of AHCY and CBS genes. Methods: We extracted peripheral venous blood from 152 patients with cerebral infarction and 152 gender- and age-matched healthy controls, and determined methylation levels of AHCY and CBS promoters using quantitative methylation-specific polymerase chain reaction. We used the percentage of methylation reference (PMR) to indicate gene methylation level. Results: We compared the promoter methylation levels of two genes (AHCY and CBS) in peripheral blood DNA between the cerebral infarction case group and the control group. Our study showed no significant difference in AHCY promoter methylation between case and control. Subgroup analysis by gender showed that the methylation level of AHCY in males in the case group was lower than that in the control group, but the difference was not statistically significant in females. In a subgroup analysis by age, there was no significant difference in the AHCY methylation level between the case and control in the young group (≤44 years old). However, the level of AHCY gene methylation in the middle-aged group (45–59 years old) was significantly higher and the aged group (≥60 years old) was significantly lower than that in the control groups. However, CBS promoter methylation levels were significantly lower in the case group than in the control group (median PMR: 70.20% vs 104.10%, P = 3.71E-10). In addition, the CBS methylation levels of males and females in the case group were significantly lower than those in the control group (male: 64.33% vs 105%, P = 2.667E-08; female: 78.05% vs 102.8%, P = 0.003). We also found that the CBS levels in the young (23–44), middle-aged (45–59), and older (60–90) groups were significantly lower than those in the control group (young group: 69.97% vs 114.71%; P = 0.015; middle-aged group: 56.04% vs 91.71%; P = 6.744E-06; older group: 81.6% vs 119.35%; P = 2.644E-04). Our ROC curve analysis of CBS hypomethylation showed an area under the curve of 0.713, a sensitivity of 67.4%, and a specificity of 74.0%. Conclusion: Our study suggests that hypomethylation of the CBS promoter may be closely related to the risk of cerebral infarction and may be used as a non-invasive diagnostic biomarker for cerebral infarction.
25 December 2025 in Research Square
Pancreatic ductal adenocarcinoma (PDAC) is an aggressive malignancy with poor clinical outcomes. Growing understanding of the roles of ubiquitin-specific peptidase 9X (USP9X) in various diseases, particularly cancer, has positioned the protein as a promising target for the development of innovative therapeutic strategies. This study examined the function of USP9X in PDAC development using PDAC cell lines and a xenograft mouse model. Nanoparticle–peptide complexes were used to target pancreatic tumors and achieve USP9X knockdown selectively. USP9X expression was positively correlated with and directly modulated programmed death ligand 1 (PD-L1) levels in cancer cells. USP9X inhibition augmented T-cell antitumor activity by promoting T-cell activation and suppressing PD-L1 expression. These findings indicated that USP9X regulates PD-L1 stability through ubiquitin-mediated degradation, enhances T-cell responses, and activates local immunity against cancer cells. Our novel therapeutic approach, designed to counteract tumor immune evasion, has the potential to inhibit tumor growth effectively.